Zydus Lifesciences Q3 & 9M FY26: Revenue +30% YoY to ₹686 Cr (Q3), EBITDA +31% at 27%; Net Debt/EBITDA 0.36x

Zydus Lifesciences Ltd reported blockbuster unaudited consolidated results.

Q3 FY26 (₹ Mn): Revenue 68,645 (+30% YoY), R&D 6,074 (8.8%), EBITDA 18,164 (+31% YoY, 26.5% margin +20 bps), Adj. Net Profit 11,109 (+9% YoY). Organic capex 4,637.

9M FY26: Revenue 195,614 (+17% YoY), R&D 15,750 (8.1%), EBITDA 59,207 (+20% YoY, 30.3% margin +80 bps), Adj. Net Profit 38,640 (+15% YoY). Organic capex 13,568.

Net debt/equity 0.11x; net debt/EBITDA 0.36x (Dec '25).

Our robust performance in 3QFY26 across key businesses reinforces the strength and scalability of our base business. Our disciplined M&A and business development strategy is translating into tangible results, laying a strong foundation for sustained value creation. Anchored in patient centricity, supported by unwavering compliance and an agile supply chain, we continue to deliver quality products globally. We remain focused on consistent execution and driving long-term shareholder value. - Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 923.10 as compared to the previous close of Rs. 887.85. The total number of shares traded during the day was 100376 in over 7043 trades.

The stock hit an intraday high of Rs. 933.40 and intraday low of 885.00. The net turnover during the day was Rs. 91923553.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals Q3FY26 Q3FY2026 9MFY26 9MFY2026 ResultUpdate